BLIS Technologies Limited (NZE:BLT)

Market Cap	19.19M
Revenue (ttm)	12.67M
Net Income (ttm)	838.00K
Shares Out	1.28B
EPS (ttm)	0.00
PE Ratio	22.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,606
Average Volume	344,052
Open	0.0150
Previous Close	0.0150
Day's Range	0.0150 - 0.0150
52-Week Range	0.0110 - 0.0220
Beta	0.29
RSI	44.19
Earnings Date	May 22, 2025

About BLIS Technologies

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It also provides its products in the ENT, immune, dental, and s...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 38
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: BLT

Financial Performance

In 2024, BLIS Technologies's revenue was 12.67 million, an increase of 9.49% compared to the previous year's 11.57 million. Earnings were 838,000, an increase of 29.72%.